These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 31005939)

  • 1. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.
    Strober B; Greenberg JD; Karki C; Mason M; Guo N; Hur P; Zhao Y; Herrera V; Lin F; Lebwohl M
    BMJ Open; 2019 Apr; 9(4):e027535. PubMed ID: 31005939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
    Callis Duffin K; Mason MA; Gordon K; Harrison RW; Crabtree MM; Guana A; Germino R; Lebwohl M
    Dermatology; 2021; 237(1):46-55. PubMed ID: 31962340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.
    Strober BE; Germino R; Guana A; Greenberg JD; Litman HJ; Guo N; Lebwohl M
    J Dermatolog Treat; 2020 Jun; 31(4):333-341. PubMed ID: 31035822
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity.
    Korman NJ; Zhao Y; Pike J; Roberts J; Sullivan E
    Dermatol Online J; 2015 Oct; 21(10):. PubMed ID: 26632793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA.
    Korman NJ; Zhao Y; Pike J; Roberts J
    Clin Exp Dermatol; 2016 Jul; 41(5):514-21. PubMed ID: 27061102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.
    Gottlieb AB; Germino R; Herrera V; Meng X; Merola JF
    Dermatology; 2019; 235(4):348-354. PubMed ID: 31141807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of psoriasis flare and remission on quality of life and work productivity: a real-world study in the USA.
    Korman NJ; Zhao Y; Roberts J; Pike J; Sullivan E; Tsang Y; Karagiannis T
    Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Satisfaction with current psoriasis treatment: misalignment between physician and patient perceptions.
    Korman NJ; Zhao Y; Pike J; Roberts J; Sullivan E; Kemhus M
    Dermatol Online J; 2016 Jul; 22(7):. PubMed ID: 27617714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
    Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):629-640. PubMed ID: 36585606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.
    Yu C; Wang G; Burge RT; Ye E; Dou G; Li J; Harrison RW; McLean RR; Kerti SJ; Bagel J
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):187-206. PubMed ID: 36385699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB; Yu AP; Signorovitch J; Xie J; Tsaneva M; Gupta SR; Bao Y; Mulani PM
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world insights for psoriasis: the association of severity of skin lesions with work productivity, medical consumption costs and quality of life.
    Lysen TS; Crombag EJGM; Lennaerts L; Makady A; Bruin RH; Mulder K; de Jong EMGJ; van Ballegooijen H
    J Dermatolog Treat; 2024 Dec; 35(1):2332615. PubMed ID: 38522860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies.
    Gooderham MJ; Elewski B; Augustin M; Iversen L; Torii H; Burge R; See K; Gallo G; Eastman WJ; McKean-Matthews M; Foley P
    J Drugs Dermatol; 2021 Apr; 20(4):394-401. PubMed ID: 33852247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis.
    Villacorta R; Teeple A; Lee S; Fakharzadeh S; Lucas J; McElligott S
    Br J Dermatol; 2020 Sep; 183(3):548-558. PubMed ID: 31840228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
    Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
    J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
    Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
    BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.